Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil

We recently published a list of 10 Stocks Wall Street Is Calling Bullish Amid Market Turmoil. In this article, we are going to take a look at where Nektar Therapeutics (NASDAQ:NKTR) stands against other stocks that Wall Street is calling bullish amid market turmoil.

The S&P 500 is down 8.6% in a month while the Nasdaq has lost nearly 13%. Markets continue to scare retail investors as stock after stock struggles to deal with the aftermath of Donald Trump’s unpredictable and aggressive policies.

While it is advisable to stay out of the market till the dust settles, one also can’t deny that it is times like these that bring opportunities. We decided to come up with a list of stocks that are expected to go up even in the existing gloomy environment.

To come up with the list of 10 stocks that Wall Street is bullish on, we looked at stocks that were recently upgraded by analysts and have performed well in the last 5 days of trading.

A scientist in lab coat testing a new biopharmaceutical drug on a microscope.

Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTR) operates as a biopharmaceutical company that discovers and develops therapies to treat autoimmune disorders. Its products include NKTR-358, PEG-CSF1, and others. The company’s stock price gained 6% in the previous year despite a downturn in the second half of the year.

Based on 9 different analyst ratings, NKTR has the highest target price of $7 which means it has the potential to grow more than six times higher from the current levels if the bull thesis holds true. The stock is currently trading at $0.91 which is 9.97% below the lowest Wall Street price target of $1.

Nektar Therapeutics (NASDAQ:NKTR) was recently upgraded by Oppenheimer from Perform to Outperform with a price target of $6. According to the analysts, the company’s stock valuation was attractive prior to the mid-stage trial results for its eczema therapy Rezpegaldesleukin. Analyst Jay Olson emphasized that Rezpeg’s distinctive profile places it in a strong position to grow in an expanding market and could offer significant benefits for eczema patients. Despite risks, investors could make 6x their money in this stock.

Overall, NKTR ranks 6th on our list of stocks that Wall Street is calling bullish amid market turmoil. While we acknowledge the potential of NKTR as a leading investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is as promising as NKTR but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires

Disclosure: None. This article is originally published at Insider Monkey.